NEW DELHI, November 21, 2024 – Abbott, the global healthcare company announced the launch of AVEIR™ VR single-chamber ventricular leadless pacemaker for the treatment of patients in India with slow heart rhythms. This pacemaker is now approved by Central Drugs Standard Control Organization (CDSCO) in India. It is also U.S. Food and Drug Administration (FDA) approved and marks a significant advancement for patient care bringing new features to patients and their physicians.
People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. While traditional pacemakers require a chest incision and pocket for the generator along with one or more insulated wires – known as cardiac leads – to deliver electricity to the heart, leadless pacemakers do not require a pocket or leads. Instead, the device is implanted directly into the heart’s right lower chamber (right ventricle) via a minimally invasive, catheter-based procedure from the groin. Therefore, there is no incision made to the chest, no wires, and no pocket in the chest for a generator.
The device has a unique mapping capability designed to allow physicians to measure electrical signals within the heart and determine the best placement of the device before final implantation. The increased projected battery longevity over current available leadless pacemakers[i][ii] opens the door to more patients. In addition, AVEIR is the only leadless pacemaker designed to be retrieved if the device needs to be replaced or therapy needs evolve.
"A leadless pacemaker offers a powerful option for the treatment of people with cardiac arrhythmias or irregular heartbeats. Leadless pacemakers address known complications associated with traditional pacemakers,” said Dr. Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital. He further added, “cardiovascular diseases like heart failure and cardiac arrhythmias form a major component of the chronic disease burden in India, and interventional therapies like pacemakers help improve patient outcomes.”
“What makes the leadless pacemaker system a unique one is that it saves patient from the risk of surgical incision, infection, pneumothorax, and wear and tear of leads over the time. It gives good longevity of more than 20 years and easy retrievability in case required. It also has the advantage of mapping for an ideal site of implantation in the right Lower chamber prior to fixing it,” says Dr. Vanita Arora, Clinical Lead Electrophysiology, Apollo Hospitals Delhi.
"The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott’s Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. " What sets this innovation apart is the impressive battery life and unique mapping capability and retrievability. Our goal is to continue to build on the introduction of AVEIR VR to provide more first-of-their-kind products in the future, revolutionizing how abnormal heart rhythms are treated."
Data from the global LEADLESS II investigational device exemption (IDE) study evaluated AVEIR VR in patients with certain abnormal heart rhythms. The results showed the device met its pre-specified primary endpoints. The findings were presented at the annual Scientific Sessions of the Asia Pacific Heart Rhythm Society (APHRS) in November 2021 and simultaneously published in the Journal of the American College of Cardiology: Clinical Electrophysiology.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. In India, Abbott was established in 1910, and is one of the country's oldest and most admired healthcare companies. With more than 12,000 employees in the country, Abbott is helping to meet the healthcare needs of consumers, patients and doctors throughout urban and rural India.
Connect with us at www.abbott.com and www.abbott.in, and on Facebook and India Facebook, LinkedIn, Instagram, X and YouTube.
The information mentioned in this document is only suggestive/for patient education and shall not be considered as a substitute for doctor’s advice or recommendations from Abbott. Please consult your doctor for more information.
Abbott Media:
Mandira Viegas: mandira.viegas@abbott.com
Gayatri Mehendale: gayatri.mehendale@abbott.com
References:
1 Reddy VY, Exner D, et al. 1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial. JACC: Clinical Electrophysiology 2023, DOI: 10.1016/j.jacep.2023.01.031
2AVEIR™ DR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600284235
3Micra‡ VR IFU M991010A001 REV. B
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
FOLLOW ABBOTT